-
1
-
-
84856158305
-
ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
-
21873419 10.1093/eurheartj/ehr236
-
Hamm CW, Bassand J-P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011;32:2999-3054.
-
(2011)
Eur Heart J
, vol.32
, pp. 2999-3054
-
-
Hamm, C.W.1
Bassand, J.-P.2
Agewall, S.3
-
2
-
-
77649126524
-
Heart disease and stroke statistics 2010 update: A report from the American Heart Association
-
20019324 10.1161/CIRCULATIONAHA.109.192667
-
Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics 2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-215.
-
(2010)
Circulation
, vol.121
-
-
Lloyd-Jones, D.1
Adams, R.J.2
Brown, T.M.3
-
3
-
-
84865271531
-
2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines
-
Writing Committee Members 22800849 10.1161/CIR.0b013e318256f1e0
-
Writing Committee Members, Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2012;126:875-910.
-
(2012)
Circulation
, vol.126
, pp. 875-910
-
-
Jneid, H.1
Anderson, J.L.2
Wright, R.S.3
-
4
-
-
33744999455
-
12 receptor
-
DOI 10.2174/138161206776361318
-
Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharmaceut Design. 2006;12:1255-9. (Pubitemid 44082134)
-
(2006)
Current Pharmaceutical Design
, vol.12
, Issue.10
, pp. 1255-1259
-
-
Storey, R.F.1
-
5
-
-
82255169699
-
Evaluating the risk-benefit profile of the direct-acting P2Y12 inhibitor ticagrelor in acute coronary syndromes
-
22104457 10.3810/pgm.2011.11.2498
-
Husted S. Evaluating the risk-benefit profile of the direct-acting P2Y12 inhibitor ticagrelor in acute coronary syndromes. Postgrad Med. 2011;123:79-90.
-
(2011)
Postgrad Med
, vol.123
, pp. 79-90
-
-
Husted, S.1
-
6
-
-
73949112820
-
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study
-
19923168 10.1161/CIRCULATIONAHA.109.912550 1:CAS:528:DC%2BD1MXhsFGgtb3N
-
Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577-85.
-
(2009)
Circulation
, vol.120
, pp. 2577-2585
-
-
Gurbel, P.A.1
Bliden, K.P.2
Butler, K.3
-
7
-
-
33646261670
-
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin
-
16476694 10.1093/eurheartj/ehi754 1:CAS:528:DC%2BD28XlsFGqtLs%3D
-
Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038-47.
-
(2006)
Eur Heart J
, vol.27
, pp. 1038-1047
-
-
Husted, S.1
Emanuelsson, H.2
Heptinstall, S.3
-
8
-
-
35548995394
-
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-st-segment elevation acute coronary syndrome. primary results of the DISPERSE-2 trial
-
DOI 10.1016/j.jacc.2007.07.053, PII S0735109707026344
-
Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844-51. (Pubitemid 350007959)
-
(2007)
Journal of the American College of Cardiology
, vol.50
, Issue.19
, pp. 1844-1851
-
-
Cannon, C.P.1
Husted, S.2
Harrington, R.A.3
Scirica, B.M.4
Emanuelsson, H.5
Peters, G.6
Storey, R.F.7
-
9
-
-
70149101223
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
-
19717846 10.1056/NEJMoa0904327 1:CAS:528:DC%2BD1MXhtFaltL%2FJ
-
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57.
-
(2009)
N Engl J Med
, vol.361
, pp. 1045-1057
-
-
Wallentin, L.1
Becker, R.C.2
Budaj, A.3
-
10
-
-
84866732231
-
ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)
-
22922416 10.1093/eurheartj/ehs289 1:CAS:528:DC%2BC38XhsFektbrE
-
Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569-619.
-
(2012)
Eur Heart J
, vol.33
, pp. 2569-2619
-
-
Steg, P.G.1
James, S.K.2
Atar, D.3
-
13
-
-
28844484174
-
Medication-related swallowing difficulties may be more common than we realise
-
Strachan I, Greener M. Medication-related swallowing difficulties may be more common than we realise. Pharm Pract. 2005;15:411-4. (Pubitemid 41771408)
-
(2005)
Pharmacy in Practice
, vol.15
, Issue.10
, pp. 411-414
-
-
Strachan, I.1
Greener, M.2
-
15
-
-
27644548513
-
Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: Randomised placebo-controlled trial
-
DOI 10.1016/S0140-6736(05)67660-X, PII S014067360567660X
-
Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised, placebo-controlled trial. Lancet. 2005;366:1607-21. (Pubitemid 41552416)
-
(2005)
Lancet
, vol.366
, Issue.9497
, pp. 1607-1621
-
-
Chen, Z.1
Jiang, L.2
-
16
-
-
35548933800
-
12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes
-
DOI 10.1016/j.jacc.2007.07.058, PII S0735109707026526
-
Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852-6. (Pubitemid 350017792)
-
(2007)
Journal of the American College of Cardiology
, vol.50
, Issue.19
, pp. 1852-1856
-
-
Storey, R.F.1
Husted, S.2
Harrington, R.A.3
Heptinstall, S.4
Wilcox, R.G.5
Peters, G.6
Wickens, M.7
Emanuelsson, H.8
Gurbel, P.9
Grande, P.10
Cannon, C.P.11
-
17
-
-
62949141274
-
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
-
19332184 10.1016/j.ahj.2009.01.003 1:CAS:528:DC%2BD1MXjslyisrg%3D
-
James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157:599-605.
-
(2009)
Am Heart J
, vol.157
, pp. 599-605
-
-
James, S.1
Akerblom, A.2
Cannon, C.P.3
|